What is fingolimod, and when did the FDA approve it?
Fingolimod (Gilenya) is an FDA-approved treatment for relapsing forms of multiple sclerosis. The FDA approval dates are tied to specific product labeling updates; the earliest approval for Gilenya was in 2010. [1]
What does the FDA-approved indication for fingolimod cover?
The FDA-approved use for fingolimod is for relapsing forms of multiple sclerosis, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease (as reflected in Gilenya’s labeling). [1]
Was fingolimod approved for pediatric patients too?
Gilenya’s labeling includes pediatric patients for specific ages and disease types as approved by the FDA, but the exact age cutoff depends on the label version in effect at the time of approval/updates. [1]
How was fingolimod first authorized (drug type and mechanism)?
Fingolimod is an oral disease-modifying therapy that works by altering lymphocyte trafficking through signaling at sphingosine-1-phosphate (S1P) receptors. This mechanism is reflected in its FDA-approved prescribing information. [1]
What safety issues are most associated with the FDA-labeled risk profile?
FDA labeling for fingolimod includes monitoring and precautions for risks such as bradycardia/heart rhythm effects, infection risk, macular edema, and other immune-related or organ-specific effects, with guidance on baseline testing and follow-up monitoring. [1]
Where can I check the current FDA approval status and label?
The most reliable source for the latest FDA-approved labeling and indication wording is the FDA Drugs@FDA record and the current Prescribing Information for Gilenya. [1]
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022527